Int Arch Allergy Immunol:儿童的皮下过敏原免疫疗法:真实生活中的依从性和COVID-19大流行对其依从性的影响

2021-05-09 AlexYang MedSci原创

皮下过敏原免疫疗法(SCIT)是治疗过敏性鼻炎、哮喘和毒液过敏的一种有效方法。由于是长期治疗,依从性对SCIT获得最大的益处至关重要。

皮下过敏原免疫疗法(SCIT)是治疗过敏性鼻炎、哮喘和毒液过敏的一种有效方法。由于是长期治疗,依从性对SCIT获得最大的益处至关重要。

最近,有研究人员确定了现实生活中儿科患者的SCIT依从性水平及相关因素。还确定了SCIT的依从性如何受到COVID-19大流行的影响,以及为什么一些患者放弃了SCIT

研究人员分析了2012年9月至2020年7月期间诊断为过敏性鼻炎、过敏性哮喘或毒液过敏的儿科患者,他们接受了SCIT治疗。研究共包括了201名儿童(66.7%为男性),第一次注射SCIT时的中位数(四分位数)为12.8岁(9.4-15.2)。COVID-19大流行前的总依从率为86.1%。SCIT随访时间短和毒液过敏性休克是退出治疗的风险因素。放弃治疗的主要原因包括搬到另一个城市/国家(32.1%),症状改善(17.8%),治疗无效(14.2%),以及不良反应(14.2%)。在COVID-19大流行期间仍在接受SCIT的108名患者中,有31人(28.7%)退出了治疗。最常见的放弃原因是害怕感染COVID-19(35.4%)和认为AIT因COVID-19大流行而停止(29%)。男性和老年是放弃SCIT的独立风险因素。

过敏原免疫治疗依从性随时间的变化情况

最后,研究人员指出,在现实生活中儿童的依从性为13.9%,比成人高。在COVID-19大流行期间,近三分之一的儿童退出治疗。在COVID-19大流行期间,男性和年长者与SCIT的退出有关

原始出处:

Elif Soyak Aytekin, Özge Soyer, Bülent E Şekerel et al. Subcutaneous Allergen Immunotherapy in Children: Real Life Compliance and Effect of COVID-19 Pandemic on Compliance. Int Arch Allergy Immunol. Apr 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1073519, encodeId=a50810e351924, content=症状改善(17.8%),治疗无效(14.2%),以及不良反应(14.2%),看来效果麻麻呀!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/AF43A7988964C1346E091DE08822DCC1/100, createdBy=1b2b1959838, createdName=jiazhoudexue, createdTime=Wed Nov 24 13:31:01 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319353, encodeId=6ca01319353f9, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Tue May 11 03:48:32 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329500, encodeId=c7e813295004c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue May 11 03:48:32 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442642, encodeId=05c4144264230, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Tue May 11 03:48:32 CST 2021, time=2021-05-11, status=1, ipAttribution=)]
    2021-11-24 jiazhoudexue

    症状改善(17.8%),治疗无效(14.2%),以及不良反应(14.2%),看来效果麻麻呀!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1073519, encodeId=a50810e351924, content=症状改善(17.8%),治疗无效(14.2%),以及不良反应(14.2%),看来效果麻麻呀!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/AF43A7988964C1346E091DE08822DCC1/100, createdBy=1b2b1959838, createdName=jiazhoudexue, createdTime=Wed Nov 24 13:31:01 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319353, encodeId=6ca01319353f9, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Tue May 11 03:48:32 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329500, encodeId=c7e813295004c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue May 11 03:48:32 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442642, encodeId=05c4144264230, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Tue May 11 03:48:32 CST 2021, time=2021-05-11, status=1, ipAttribution=)]
    2021-05-11 fyxzlh
  3. [GetPortalCommentsPageByObjectIdResponse(id=1073519, encodeId=a50810e351924, content=症状改善(17.8%),治疗无效(14.2%),以及不良反应(14.2%),看来效果麻麻呀!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/AF43A7988964C1346E091DE08822DCC1/100, createdBy=1b2b1959838, createdName=jiazhoudexue, createdTime=Wed Nov 24 13:31:01 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319353, encodeId=6ca01319353f9, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Tue May 11 03:48:32 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329500, encodeId=c7e813295004c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue May 11 03:48:32 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442642, encodeId=05c4144264230, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Tue May 11 03:48:32 CST 2021, time=2021-05-11, status=1, ipAttribution=)]
    2021-05-11 膀胱癌
  4. [GetPortalCommentsPageByObjectIdResponse(id=1073519, encodeId=a50810e351924, content=症状改善(17.8%),治疗无效(14.2%),以及不良反应(14.2%),看来效果麻麻呀!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/AF43A7988964C1346E091DE08822DCC1/100, createdBy=1b2b1959838, createdName=jiazhoudexue, createdTime=Wed Nov 24 13:31:01 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319353, encodeId=6ca01319353f9, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Tue May 11 03:48:32 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329500, encodeId=c7e813295004c, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue May 11 03:48:32 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442642, encodeId=05c4144264230, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Tue May 11 03:48:32 CST 2021, time=2021-05-11, status=1, ipAttribution=)]

相关资讯

Ear Nose Throat J:突发感音神经性听力损失儿童的临床特征与内淋巴水肿的相关性

最近,有研究人员调查了突发感音神经性听力损失(SSNHL)患儿的临床特征与内淋巴水肿(EH)之间的相关性。

Radiology:如何同时提高小儿CT图像质量并降低辐射剂量?人工智能给了我们答案

在CT中,图像质量的提高和辐射剂量的降低的是一个固有的对抗过程,降低辐射剂量往往以牺牲图像质量为代价。

Radiology:住院患儿静脉注射碘造影剂真的有那么可怕吗?

在儿童CT检查中,通常静脉给予低渗和等渗碘造影剂(ICM)以增强血管、脏器和病变的对比度。

Braz J Otorhinolaryngol:巴西儿童早期听力损失的成因

听力损失的病因取决于所研究的人群以及所分析地区的种族和社会经济状况。病因诊断有助于改进预防措施和早期识别这种缺陷。

JCEM:2006-2016年美国儿童糖尿病酮症酸中毒入院的全国趋势

美国儿童DKA入院率上升了40%,弱势群体风险最高。进一步的研究应归纳这些人群所面临的挑战,以为制定减轻其DKA风险的干预措施提供参考,并解决全国范围内DKA发生率上升的问题。

JAHA:环境空气污染对儿童和青少年血压的影响

短期和长期接触某些环境空气污染物可能会升高儿童和青少年的BP。